Blagosklonny goes on to write that even though rapamycin may reverse some manifestations of aging, it is more effective at ...

The drug blocks the activity of a protein known as mammalian target of rapamycin (mTOR), which promotes proliferation through the activation of proteins such as S6 kinase. Although the mTOR ...

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the presentation of its investigational therapy QTORIN™ ...

Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

Bryan Johnson, the anti-aging influencer, halted his Rapamycin regimen after five years due to adverse side effects like ...

In a candid admission shared via a new video on his YouTube channel, Bryan Johnson acknowledged that a critical component of ...

In particular, the mechanistic target of rapamycin (mTOR) pathway has been tied to multiple age-related chronic disease processes, such as declining immune function, diminishing bone mineral ...

The oral presentation will highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN™ rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic ...